首页> 外文期刊>Frontiers in Immunology >Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
【24h】

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication

机译:具有主要免疫缺陷的患者是脊髓灰质炎病毒库和根除脊髓灰质炎的风险

获取原文
获取外文期刊封面目录资料

摘要

Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.
机译:已从暴露于口服脊髓灰质炎病毒疫苗(OPV)的原发性免疫缺陷(PID)患者中分离了与免疫缺陷相关的疫苗衍生脊髓灰质炎病毒(iVDPV)。患者可能排泄脊髓灰质炎病毒株数月或数年;排泄的病毒通常与亲本OPV高度不同,并已显示出与野生病毒一样的神经毒性。因此,这些患者代表了根除后时代神经毒性脊髓灰质炎病毒传播的潜在库。为了支持WHO的建议,以更好地估计PID中脊髓灰质炎病毒分泌物的流行,并表征这些菌株的遗传进化,对13个使用OPV的国家的635名患者进行了研究,其中包括570例原发性抗体缺陷和65例联合免疫缺陷。在4天内收集两个粪便样品,测试肠病毒,并对脊髓灰质炎病毒阳性样品进行测序。十三名患者(占2%)分泌了脊髓灰质炎病毒,大多数在发现感染后不到2个月。五个(0.8%)被归类为iVDPV(仅在合并的免疫缺陷和大多数脊髓灰质炎病毒血清型2中)。在30例患者中检出了非脊髓灰质炎性肠病毒(4.7%)。与一线抗体缺乏症相比,合并免疫缺陷症的患者脊髓灰质炎病毒清除延迟的风险增加。通常,在暴露于OPV之后的短时间内,在合并免疫缺陷的受试者中检测到iVDPV,大多数时间少于6个月。应当加强对PID患者中脊髓灰质炎病毒排泄的监测,直到根除脊髓灰质炎得到证明并停止使用OPV。在中低收入国家,PID患者的存活率正在提高,而且iVDPV排泄物的识别频率更高。目前正在开发中的抗病毒药物或增强的免疫疗法是管理延长排泄物及其对小儿麻痹症终末期的风险的唯一潜在手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号